Show simple item record

Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma

dc.contributor.authorAmato, David A.
dc.contributor.authorBruckner, Howard
dc.contributor.authorGuerry, DuPont IV
dc.contributor.authorAsh, Arlene S.
dc.contributor.authorFalkson, Geoffrey
dc.contributor.authorBorden, Ernest C.
dc.contributor.authorCreech, Richard H.
dc.contributor.authorSavlov, Edwin D.
dc.contributor.authorCunningham, Thomas J.
dc.date2022-08-11T08:10:41.000
dc.date.accessioned2022-08-23T17:16:49Z
dc.date.available2022-08-23T17:16:49Z
dc.date.issued1987-01-01
dc.date.submitted2010-07-01
dc.identifier.citationInvest New Drugs. 1987;5(3):293-7. <a href="http://dx.doi.org/10.1007/BF00175301">Link to article on publisher's site</a>
dc.identifier.issn0167-6997 (Linking)
dc.identifier.doi10.1007/BF00175301
dc.identifier.pmid3667165
dc.identifier.urihttp://hdl.handle.net/20.500.14038/47484
dc.description.abstractIn this Eastern Cooperative Oncology Group (ECOG) phase II study, dibromodulcitol (DBD) and a combination of actinomycin D, hydroxyurea, and cyclophosphamide (AHC) were compared with methyl-CCNU, the current ECOG standard, in patients who had received no prior chemotherapy for disseminated malignant melanoma. The response rates were 6% (3/50) for AHC, 9% (3/34) for DBD, and 14% (7/49) for methyl-CCNU. Median survival times were 4, 5, and 6 months, respectively. Neither regimen appears to offer any advantage over methyl-CCNU as front-line therapy for patients with disseminated melanoma.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=3667165&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1007/BF00175301
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjecteffects
dc.subjectCyclophosphamide
dc.subjectDactinomycin
dc.subjectDrug Evaluation
dc.subjectFemale
dc.subjectHumans
dc.subjectHydroxyurea
dc.subjectMale
dc.subjectMelanoma
dc.subjectMiddle Aged
dc.subjectMitolactol
dc.subjectSemustine
dc.subjectBiostatistics
dc.subjectEpidemiology
dc.subjectHealth Services Research
dc.titlePhase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma
dc.typeJournal Article
dc.source.journaltitleInvestigational new drugs
dc.source.volume5
dc.source.issue3
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/qhs_pp/620
dc.identifier.contextkey1378765
html.description.abstract<p>In this Eastern Cooperative Oncology Group (ECOG) phase II study, dibromodulcitol (DBD) and a combination of actinomycin D, hydroxyurea, and cyclophosphamide (AHC) were compared with methyl-CCNU, the current ECOG standard, in patients who had received no prior chemotherapy for disseminated malignant melanoma. The response rates were 6% (3/50) for AHC, 9% (3/34) for DBD, and 14% (7/49) for methyl-CCNU. Median survival times were 4, 5, and 6 months, respectively. Neither regimen appears to offer any advantage over methyl-CCNU as front-line therapy for patients with disseminated melanoma.</p>
dc.identifier.submissionpathqhs_pp/620
dc.contributor.departmentDepartment of Quantitative Health Sciences
dc.source.pages293-7


This item appears in the following Collection(s)

Show simple item record